Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of panitumumab plus irinotecan in KRAS wild-type metastatic colorectal cancer refractory to irinotecan-based chemotherapy
2009-010833-27Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and irinotecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective response rate. Started May 2009; status: completed.
02
Drugs
panitumumabirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-010833-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010833-27.